Xsolla Partners With iBLOXX to Promote Their Web3 Games Globally and Drive Launch of Upcoming Third-person Shooter Title StrayShot
11.12.2024 10:00:00 CET | Business Wire | Press release
iBLOXX Leverages Xsolla’s Monetization, Marketing, And Distribution Tools To Showcase Games Across MENA
Xsolla, a global video game commerce company, announces a new partnership with iBLOXX, a studio specializing in developing next-generation multiplayer games on the blockchain. The alliance was cultivated at the PGC Dubai event in April 2024, underscoring Xsolla’s continuous commitment to fostering long-term growth within the Middle East and Northern Africa region’s rapidly expanding gaming ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211854266/en/

(Graphic: Xsolla)
This strategic collaboration starts with supporting the launch of their new title, StrayShot. This thrilling third-person shooter game for PC and mobile allows players to step into the boots of a Bounty Hunter, ready to take on rivals in intense matches in several game modes. Players can team up with friends or go solo to fight other players in an epic battle for survival and earn exclusive rewards. This game is unique as it includes Web3 elements, NFTs, and tournaments, all of which Xsolla has solutions to support, particularly when it comes to subscription and virtual currency.
As a pivotal force within the MENA gaming ecosystem, Xsolla continues to leverage its advanced tools and platforms to empower partners and developers. Through this collaboration with iBLOXX, Xsolla is set to elevate the game studio’s reach and performance by providing key monetization, marketing, and distribution capabilities. Xsolla’s payments and monetization technology and expertise will ensure StrayShot gains maximum exposure while optimizing player engagement and revenue generation across multiple channels.
Chris Meredith, SVP EMEA at Xsolla, expressed his enthusiasm about the new partnership, commenting, “It’s great to work with a mature studio in the region with such a long-standing commitment to the growth and development in MENA,” he added. “This partnership will bring their groundbreaking titles and the launch of their newest title, StrayShot, to a wider audience, putting them firmly on the map as a major player in the industry.”
Domenik Maier, CEO of iBLOXX, stated: “We’re thrilled to join forces with Xsolla. Their support will be a game-changer for the upcoming launch of StrayShot, ensuring that it reaches a much larger, more engaged audience!”
The collaboration highlights Xsolla’s unwavering commitment to supporting long-term partnerships that contribute to the sustained growth and innovation of the regional gaming landscape. By partnering with iBLOXX, Xsolla is further enhancing its position in the MENA market, where gaming is experiencing rapid evolution and expansion.
For more information on Xsolla's partnership with iBLOXX to promote Web3 games globally and drive the launch of the upcoming third-person shooter StrayShot, visit xsolla.blog/xipw.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For additional information and to learn more, please visit xsolla.com.
About iBLOXX
iBLOXX is a leading innovator in Web3 gaming, leveraging its extensive background in decentralized technologies and quantitative finance to craft robust, player-driven game economies and deeply engaging virtual worlds. By blending cutting-edge blockchain infrastructure with innovative design principles, iBLOXX aims to deliver richer gaming experiences — where players truly own their in-game assets and game worlds evolve in tandem with their communities.
For additional information about their upcoming title StrayShot, please visit StrayShot.game.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211854266/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release
- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release
New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release
From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge
RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release
A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom